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Abstract This article describes the judgements used to interpret evidence in
evidence-based medicine (EBM) and health technology assessment (HTA). It outlines
the methods and processes of EBM and HTA. Respectively, EBM and HTA are approaches
to medical clinical decision making and efficient allocation of scarce health resources.
At the heart of both is a concern to review and synthesise evidence, especially evidence
derived from randomised controlled trials (RCTs) of clinical effectiveness. The driver of
the approach of both is a desire to eliminate, or at least reduce, bias. The hierarchy of
evidence, which is used as an indicator of the likelihood of bias, features heavily in the
process and methods of EBM and HTA. The epistemological underpinnings of EBM and
HTA are explored with particular reference to the distinction between rationalism and
empiricism, developed by the philosopher David Hume and elaborated by Immanuel
Kant in the Critique of Pure Reason. The importance of Humian and Kantian principles
for understanding the projects of EBM and HTA is considered and the ways in which
decisions are made in both, within a judgemental framework originally outlined by Kant,
are explored.
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Introduction
This article considers the way in which judgements are used to interpret evidence
and make decisions in evidence-based medicine (EBM) and health technology
assessment (HTA). Specifically, it will be shown that the judgements in both EBM
and HTA may be understood with reference to the ideas of rationalism and
empiricism, as outlined in the writings of Hume (1748) and subsequently ela-
borated by Kant (1781). This essay develops this theme by describing the prin-
ciples of EBM and HTA. It goes on to examine the problem of uncertainty
associated with bias that EBM and HTA seek to minimise and explores the ways
in which the ideas of empiricism and rationalism are integral to the way that
EBM and HTA operate. The significance of the concepts of internal and external
validity is examined and the role of deduction and induction described. The
article goes on to suggest that the ideas of Hume and Kant can help explain the
interpretation and decision-making process in both EBM and HTA, as well as
illuminating some of the tensions that arise in doing EBM and HTA.
An Outline of EBM and HTA
EBM is conventionally defined as ‘y the conscientious, explicit and judicious
use of current best evidence in making decisions about the care of individual
patients’ (Sackett et al, 1996, p. 71). The underlying principle of EBM is to use
the evidence that is the least likely to be biased as the basis for clinical decision
making. The rationale behind this is that medical interventions are inherently
risky to patients and very costly for whoever has to pay for them. EBM therefore
starts from the premise that the platform for the practice of medicine should
be the best available (meaning least biased and therefore most trustworthy)
evidence. This, it is argued, offers the patient protection from medical incom-
petence, from other risks and from the inflated claims of drug effectiveness
made by a profit-driven pharmaceutical industry (Greenhalgh, 2001).
HTA is the first cousin of EBM. Its origins lie in the escalating costs of
pharmaceuticals across the globe and the need to find transparent, fair and
scientifically robust ways of determining whether new drugs are effective and
cost effective (Sorensen et al, 2010). It has its own Annual International
Conference. There are many agencies around the world that sit between the
pharmaceutical industry and the payers, be they governments or insurance
companies. These agencies judge the clinical and cost effectiveness of these
new technologies. HTA essentially uses the same approach as EBM, but with a
very strong health economics component, usually cost utility analysis, as part of
the decision-making process. The most well-known EBM/HTA agency in the UK
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is The National Institute for Health and Clinical Excellence (NICE) (Kelly et al,
2010).
Over the years, there have been some important contributors to the ideas of
EBM and HTA. One of the most interesting and influential is Archie Cochrane,
a chest physician, fighter against Franco’s forces in the Spanish Civil War,
prisoner of the Germans after the Battle of Crete in 1941, supporter in the early
days of the British Sociological Association’s Medical Sociology Group, first
President of the Faculty of Public Health and all round iconoclast. In his book
Effectiveness and Efficiency: Random Reflections on Health Services, he asked
a set of simple questions (Cochrane, 1972). Do we know whether intervention x
for condition y is effective? How do we know it is effective? How do we know
whether it is more or less effective than intervention z? On what basis do we
make that judgement of effectiveness? Do we know what it costs? Is it cost
effective? If it is not cost effective, why is it still being used? What are the
dangers posed to patients of treatments about which we are scientifically un-
certain? Are the treatments dangerous? Why are we using potentially dangerous
or worthless treatments?
His suggestion that the randomised controlled trial (RCT) should be the
starting point for answering these questions, although now part of the con-
ventional evidence-based wisdom, did not immediately find favour. In 1972,
when Effectiveness and Efficiency was published, the RCT was still then the
exception rather than the rule, as the basis for medical decision making and
health economics did not form any component of resource allocation in British
health services. Cochrane’s argument that some kind of cost effectiveness
consideration should be a part of clinical decision making was initially taken
seriously by few commentators. He was highly critical of the waste he observed
in the use of unproven technologies and, although the kind of economics he
advocated in Effectiveness and Efficiency now seems rather crude, he had in
essence asked the question that few had had the good sense to ask before.
He made common cause with Alan Williams, professor of economics at the
University of York, who did much to develop the principles of cost utility
analysis as a means of understanding and doing resource allocation in health
care better. Williams’ work and that of his many colleagues and students at the
University of York laid the foundations of modern British health economics and
the York group still play a very important role in HTA internationally (Culyer
et al, 1972; Drummond et al, 2005, 2007; Lomas et al, 2005; Culyer, 2006).
Cochrane was right about the RCT. It does offer the best assessment of the
question of clinical effectiveness. To determine the effectiveness of a drug
therapy and some other types of intervention, the RCT provides more certainty
than any other method because it maximises internal validity by reducing bias
(Campbell and Stanley, 1966). It is a method that is designed to allow the
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reasonable conclusion that the effect that is being witnessed is the consequence
of the intervention. By controlling out of the process factors that could con-
taminate the relationship between the independent and dependent variable, the
observer has as much certainty as possible that the relationship is real rather
than an artefact of the research process or some other variables confounding
the relationship. It also allows degrees of effect or effect size to be estimated.
Trials of effectiveness form the platform for the subsequent economic analysis
of cost effectiveness. The results of trials are never absolutely certain, however,
because even the best trials are flawed in various ways. In addition, the size and
time scale of most trials mean that they cannot detect all possible adverse
reactions, and as more and more observations accumulate original observations
may be modified (Rawlins, 2008). Moreover, trials are not always the appro-
priate method to investigate the question (Black, 1996; Glasziou et al, 2007;
Vandenbroucke, 2008). However, for the purposes of assessing clinical effec-
tiveness, the double-blind RCT sets a threshold that no other method has yet
surpassed.
Therefore, the RCT is the starting point methodologically for EBM and HTA.
However, EBM and HTA are much more than just RCTs. As the evidence-based
approach has evolved, a number of practices have developed. In schematic
terms, these involve a sequence of activities. The sequence depends on the pre-
existence of a body of primary research, some of which will be RCTs. Then, and
the first stage in the sequence, a clinical problem is expressed as a question, for
example – what is the comparative effectiveness of different treatments for
a particular disease? It is usual to use the so-called PICO framework to do this.
This involves specifying the population, the intervention, the comparator and
the outcome.
Second, the potential answer to the question is sought from the peer-reviewed
scientific literature – not opinion or current practice, but empirical evidence that
has been subject to the detailed scrutiny of peer review. Modern search tech-
niques and search engines, as well as comprehensive if not exhaustive data-
bases, allow the world literature to be searched for the evidence and also help to
preclude the possibility that findings will be out of date or US or UK centric. The
literature searching is done systematically using highly sophisticated computer-
based search protocols according to clear and explicit inclusion and exclusion
criteria. The process is replicable, transparent and auditable (Egger et al, 2001;
Greenhalgh, 2001; Centre for Reviews and Dissemination, 2008).
Third, the evidence that is found in this way is then subject to critical
appraisal using well-defined methods designed to weed out bias. The focus is
on internal validity. Studies are ranked in the hierarchy of evidence. The hier-
archy of evidence represents levels of types of evidence where internal validity
is improved at each succeeding step up the hierarchy. With each step up the
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hierarchy, the chances of bias are lessened. RCTs score highly because their
raison d’eˆtre is the controlling out of factors, which can cause bias.
Fourth, the studies are then assessed for quality within the levels of the
hierarchy (Egger et al, 2001; Greenhalgh, 2001). Sometimes, the data extracted
from the studies ranked highest (good RCTs) are synthesised in a procedure
called meta-analysis. Meta-analysis involves summing the results of trials
together in order to determine the overall result of the accumulated evidence.
Even without formal meta-analysis, there are a number of techniques that
allow comprehensive accounts of the accumulated evidence to be provided
(NICE, 2009). Following this, it is a relatively straightforward matter, at least in
principle, to determine the answer to the original comparative effectiveness
question. Finally, all of this can be assessed for its cost effectiveness using the
principles of cost utility analysis.
The practitioners of the evidence-based approach usually take it as self-
evident that EBM is superior to other forms of medical decision making and
other forms of resource allocation because of the scientific and rigorous nature
of their practice. The practitioners of EBM tend to start with a very practical and
praiseworthy precept, which is that the recipients of medical treatments deserve
the best and safest treatments that are available. These can be determined using
scientific methods to search, synthesise, appraise and analyse the cumulative
evidence. Further, they acknowledge that until relatively recently the degree
of variation in medical practice and wide differences in the drug prescribing
behaviour of doctors were not grounded in science. Occupational practices were
embedded in learning in medical school, the dominance of influential medical
professors and other medical leaders and the influence of the pharmaceutical
industry. In addition, as the growth in the volume of scientific medical infor-
mation has accelerated exponentially since the 1960s, doctors simply could not
keep up with the amount of new information. Even the most conscientious and
assiduous physician or decision maker could never hope to keep pace with the
growing amount of evidence. The systematic review and synthesis of the best
available evidence offers a means of looking at accumulated findings from
multiple investigations and, in part at least, solves the problem of information
overload.
HTA is based on the principle that markets alone are not the optimal means of
resource allocation in health care and that the principles of fairness and
transparency should be paramount. Cost utility analysis provides a method that
embraces costs through the concept of the Quality Adjusted Life Year. This
combines a measure of quality of life with an estimate of what society is willing
to pay for treatments, to produce an assessment of how to allocate resources
fairly. This idea goes beyond a simple measure of costs and allows comparisons
to be made between different treatments. The process acknowledges that there
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is always a limited budget to pay for health care and that demand for scarce
health care resources outstrips the ability of individuals or society to pay for all
possible treatments. It also embraces the idea that the improvements whether
measured in the direct effect of the drug or the patient’s quality of life is not
uniform and that, therefore, some means of comparison between different
treatments is required. The cost utility measure provides a mechanism to weave
a way through this complexity (Drummond et al, 2005).
The guideline movement has sprung up in parallel with EBM and HTA. A
guideline is an evidence-based protocol, providing doctors and others involved
in the care of patients with descriptions of optimal algorithms for pathways of
care and interventions. A guideline is based on cumulative findings from sys-
tematic reviews. A guideline will in theory encapsulate the most up-to-date and
best evidence and help eliminate the variation in medical practice, which
characterised earlier generations. The Cochrane Collaboration, a worldwide
network of systematic reviewers producing up-to-date reviews of many hun-
dreds of different aspects of medical care and interventions, is a major and
easily accessible resource to underpin those doing EBM and HTA. In the UK, the
Centre for Reviews and Dissemination at the University of York is a major UK
resource underpinning EBM, HTA and guidelines.
EBM has undoubtedly brought improvement to a range of patients’ experi-
ences and reduced some of the risks associated with medical care. It has also put
the funding of new technologies on a fairer and more transparent basis where
HTA is used properly. For the most part, the proponents of the EBM approach,
the vast majority of whom are trained initially in biomedicine, statistics or
economics, do not tarry with the theoretical niceties with which this article is
concerned. Instead, the refinement of the methodology of trial design, processes
of literature searching and development of clinical guidelines have been central
to the methodological concerns of EBM. The logic of the scientific methods used
is assumed to be optimal, to be linear and to be progressive. There is no sense at
all of science as a social or historical product and of ways of knowing and under-
standing as sociologically or historically grounded (Pickstone, 2007). Therefore,
underlying sociological, epistemological and philosophical questions remain
little discussed. However, there are some extremely interesting and important
issues to which the whole business gives rise. This article explores one of these –
the basis of the interpretations and judgements involved.
Uncertainty
EBM and HTA depend on the principle of evidence accumulation. In other
words, they make a virtue out of the exponential growth in medical knowledge.
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The idea is that the greater the number of observations, the greater the degree of
accuracy about that which is being observed and the greater the chance of the
elimination of uncertainty. Further, if multiple studies with multiple results are
pooled, then there is an even better chance of the results being averaged out
in an optimally accurate way. This is a way of dealing with uncertainty. It
recognises explicitly that single observations may be unreliable and that multi-
ple observations offer protection against outliers. It also presumes that repeated
observations will in the long run be more likely to be a truer representation of
the outcomes of interest, and those initial and single observations are a poor
basis for inductive reasoning.
The question of uncertainty has several dimensions. Underlying the reason
why observations vary in drug trials is individual human biological and genetic
variation. Each time a drug is administered to an individual patient, it produces
biochemical changes in the human body. Some of these may be efficacious in
terms of the desired outcome – some will not be. The human body is a dynamic
biological system, and different human bodies vary in the way in which they
respond to the administration of any pharmaceutical agent. This is by virtue of
metabolism, nutritional status, age, genetics, intercurrent disease, other drugs
being used and the effects of the lifecourse, as well as the biochemical interaction.
There will, therefore, always be a range of ways in which the human organism
responds. This is why a drug that has a therapeutic benefit in one patient will not
necessarily always work in the same way in all patients. The purpose of the
clinical trial is to determine whether, on average, it will work for most or for
some subset in the population. The idea of biological variation is intrinsic to
the business of doing medical research and indeed medicine more generally. The
concepts of efficacy and effectiveness capture this idea. Efficacy deals with the
question of whether or not a particular intervention works under highly con-
trolled laboratory or laboratory-like conditions. Effectiveness is concerned with
the degree to which it works on average in real-world settings in clinical practice.
A trial is just one aggregated average overall observation and looking at the
results of one trial may mislead. The phenomena that early trials tend to
achieve better results than later ones, that positive findings tend to get reported
more readily than negative ones in the scientific literature and that all sorts
of Hawthorne, placebo and reactivity effects will be at work (Blalock, 1970;
Orne, 1970) mean that it is now considered much wiser, if possible, to look
to the multiple trials of the same agent to see what on average the result is of
all the trials, the sine qua non of EBM. This narrows down the possibility
that one early trial result will be an outlier. And, obviously, within the method,
great pains are taken to avoid placebo and Hawthorne effects by blinding the
intervention and control subjects and their doctors as to which are taking the
active drug.
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The Problem of Observation
However, the question of uncertainty goes still further than biological variation, to
the process of observation itself. This problem was formulated more than 250
years ago in Enlightenment philosophy most clearly by David Hume (Hume,
17481) in Scotland, and later by Immanuel Kant (Kant, 17872) in Prussia. Both
were influenced by the then emerging science of optics. Hume and Kant argued
that there is a distinction to be made between the observation and the thing that is
being observed. What we observe – the observation – is a representation in our
mind, which comes to us via our senses and any scientific instrument we are
using, of the real thing that is being observed. Applied to any process of scientific
observation, the distinction made by Hume and Kant indicates that there is an
underlying reality, but our ability to perceive or observe it is always partial. All
scientific data are but representations of reality. Our observations must not be
confused with reality. Further, this observational process produces distortion and
bias because we are fallible observers and the tools we use to do the observation,
whether our own senses or some scientific instrument, will be limited by our
human capacity to observe and interpret and the technology we are using. This
applies equally well to a doctor listening to a heartbeat through a stethoscope and
inferring heart disease, to the results of a trial, to the observation of a specimen
under a microscope or to perceiving a landscape in the distance. In the case of a
clinical trial of a drug, the drug has a real biochemical reaction and there will be
average overall effects in population groups in the trial, but the data from the trial
are ways of representing that reality in two-dimensional space – on screen or on
paper. That representation will in turn require interpretation: a process of inferring
what the underlying biological reality is on the basis of the two-dimensional
representation of it – on paper or on screen.
Hume (1748, p. 79), despite being an avowed empiricist, argued that expe-
rience and observation were fallible guides to the real world. In other words,
empirical observation is subject to distortion. We needed, he suggested, to
proportion our belief in the evidence before us – our observations – on the basis
of past observations, the weight of evidence, probability (what he rather con-
fusingly called moral reasoning) and the similarity of observations to previous
observations (1748: 80). For Hume, there was always some process going on of
what today we would call social construction. This does not mean that the
world around us is illusory. It means that our ability to observe real things is
always partial. Kant embraced the same idea. In Kant’s terms, we can only
perceive things as they appear to be – what he called phenomenon – rather than
as they really are – what he called noumenon.
This fundamental position is simultaneously central to EBM and ignored
by it. It is central because EBM acknowledges that single observations are
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potentially unreliable and that the best (but not necessarily final) account of
the relationship between the drug and the outcome is obtained by multiple
observations. This is firmly in the Humian/Kantian tradition. However, EBM
seldom goes the stage further and questions the reality of the evidence itself. It
tends to treat the evidence not as a proxy for reality, but as if it were reality. This
is to confuse empirical observation with reality itself in what appears to be a
crude form of positivism. All science can ever realistically do empirically is
describe the observations made as best and as accurately as possible. The data
from a trial are not the real underlying biological process – they are the best
available approximation of it. Consequently, not only can bias never be elimi-
nated completely, but it is also a feature intrinsic to all scientific observation.
EBM strives to reduce bias as if its complete elimination were possible. All
observation involves distortion because by its very nature the act of observation
changes that which we observe. This, EBM never acknowledges. Instead, the
evidence is given an ontological status as something real, not as a representa-
tion of the underlying reality. Further, the principles of the hierarchy of evidence
designed to eliminate bias are premised on the idea that if only bias can be
eliminated, then the truth will emerge. This is, at least in Humian and Kantian
terms, impossible.
Interpreting Uncertain Observations
The issues that the Enlightenment philosophers can assist us with, however, go
further and actually help to get EBM off the hook of the accusation of naı¨ve
positivism and confusing facts and observations. Hume (1748, pp. 17–25) divi-
des reasoning into (i) that concerned with the relations between ideas called
demonstrative reasoning or rationalism, and (ii) that concerned with matters of
fact called factual reasoning or empiricism. The first is a priori, that is, precedes
observation. This form of reasoning for Hume includes geometry, arithmetic
and algebra. Matters of fact on the other hand are a posteriori and derived from
evidential observations (1748: 18) usually involving some assessment of
cause and effect (1748: 19). These are a posteriori – after the fact or after the
observation. Demonstrative reasoning is about the relations between ideas
(1748: 25). Demonstrative reasoning is deductive. It proceeds with absolute
certainty, based as it is on the logical relations between ideas. Factual reasoning
is inductive and involves drawing apparently reasonable but not logically cer-
tain conclusions based on the available and incomplete evidence (Millican,
2007, p. xxxvii).
The rhetoric of EBM is located firmly in the empiricist, matters of fact camp.
Most of the proponents of EBM would see themselves as dealing with matters
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of fact or real things. However, there are very strong elements of rationalist
thought at the heart of EBM. The principles of the elimination of the possibility
of bias in the hierarchy of evidence, of the rule-driven principles of guideline
development and appraisal are based on an ideal version of the scientific
method, which owe more to the logical precepts of the a priori relations of ideas
than they do to messy empirical observation. Hume’s warnings that induction
was probabilistic and that, therefore, interpretative processes were required to
understand the data are the underdeveloped component in EBM. Every time an
empirical statement is made, a set of rationalist judgements have been used to
make sense of the data and to interpret the evidence. Although EBM has been
particularly effective at elucidating the empirical end of things, it has been
much less reflective about the rationalist processes it uses.
Although Hume and Kant agree on the object–observation distinction and are
agreed that knowledge is either rationalist or empiricist, after that they part
company. Hume, in the end, argued for the superiority of the empiricist method.
The Enquiry ends with his famous words. ‘If we take in our hand any volume of
divinity or school metaphysics, for instance; let us ask, Does it contain any
abstract reasoning concerning quantity or number? No. Does it contain any
experimental reasoning concerning matters of fact and existence? No. Cast it
then into flames. For it can be nothing but sophistry and illusion’.
Kant is less convinced. An admirer of Hume, but he was much less certain
that empirical knowledge on its own could be so easily divorced from ration-
alism or what he called pure reason (Kant, 1787, p. 41). Kant argues that there
must be knowledge that is independent of experience, which is not a posteriori
(Kant, 1787, pp. 42–43) because, without some a priori knowledge, we would
be unable to make sense of what we observe (Kant, 1787, p. 42). A priori know-
ledge is independent of experience, whereas empirical a posteriori knowledge is
not (Kant, 1787, p. 43; Weldon, 1958, p. 101). For Kant, experience is neither the
product of pure reason nor of empirical induction; it is both. All knowledge
begins with experience, but not all knowledge is derived from experience, the
bridge is the interpreting observer.
The Types of Judgements Made About Evidence
Kant argues that we need some kind of criteria to distinguish between pure and
empirical knowledge (Kant, 1787, p. 43). To explore the relationship between
the two forms of knowledge, one based on pure a priori reasoning and one
based on observation, Kant develops an argument about what he calls judge-
ments or rules (Korner, 1955, p. 104), meaning the way we interpret the objects
of our perception. Judgements can be analytic or synthetic (Korner, 1955). An
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analytic judgement is one in which the meaning of the predicate is included
in the meaning of the subject (Kant, 1787, pp. 45–49; Ward, 2006, p. 16).
A simple example of this is ‘all bachelors are men’. The same meaning is intri-
nsic in each term – men and bachelor – because the definition of bachelor
means an unmarried man. Analytic judgements like this are a priori, and to
deny them is self-contradictory (Korner, 1955; Ward, 2006, p. 18).
On the other hand, judgements may be synthetic. In this case, the meaning of
the predicate is not contained in the subject (Ward, 2006, p. 16). Two things that
are not intrinsic to each other are brought together (Korner, 1955). An example
of this would be ‘the book is blue’. We are bringing together two ideas, book and
blue. They are not intrinsic to each other because books can be of any colour
and the colour blue could apply to many different objects (Guyer, 2006). The
blue book on my table is one specific object located in space and time, observed
empirically. The book is blue is a synthetic judgement because the idea blue is
not intrinsic to the idea book (Guyer, 2006, p. 47). Synthetic judgements are
a posteriori because they are established by recourse to experience (Ward, 2006,
p. 18), in this instance of books and of colours. Simple a priori knowledge is
analytic, and empirical a posteriori knowledge is synthetic.
However, Kant suggested that it is more complex than this because some a
priori judgements are synthetic not analytic (Kant, 1787, p. 51). For Kant, these
synthetic a priori judgements are the fundamental judgements or precepts of
geometry, mathematics, natural science and metaphysics, that is, they are more
than just contained in the subject and predicate and cannot be determined on
the basis of experience alone (Guyer, 2006, p. 47; Ward, 2006, p. 19). For Kant,
the most important ideas of this type relate to space and time (Korner, 1955).
A priori rationalism provides the conceptual architecture in the form of synthetic
a priori judgements and is the basis for empirical science.
The apparently simple distinction made by Hume between rationalism and
empiricism therefore turns out for Kant to be more complex. For Kant, there
were three elements involved in knowing and understanding and used in the
process of interpreting sense data or scientific evidence – to recap – (i) analytic
a priori judgements, (ii) synthetic a posteriori judgements and (iii) synthetic
a priori judgements. These judgements or rules are quite helpful for considering
the processes and practices of EBM.3
Therefore, following Kant’s argument, first there are the analytic a priori
judgements. These are a very significant part of the EBM armoury. They are the
logical and methodological givens. They are self-referential in the sense that
by definition they are true and to deny them would be self-contradictory. The
most important analytic a priori propositions in EBM are those that give rise to
the hierarchy of evidence. The hierarchy is the operationalisation of the a priori
analytic principle, and fundamentally rationalist idea, that there is a true and
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real relationship between phenomena and that extraneous or confounding
factors mask that true relationship. By reducing bias, we can get closer to that
real relationship. The problems described in the previous sections of this article
relating to the biases that arise as a consequence of the process of observation,
or the difficulties surrounding uncertainty or the fallibility of the human obser-
ver, are thought of, in this view, as masking our ability to see the true nature of
things. The methodological task following from this is to try to limit the impact
of such things in order to reduce uncertainty and bias and to see things as they
really are. The concept of efficacy is premised on this precept.
The idea that there are true and real relationships between things, usually
defined as the independent and dependent variable, is the central a priori
analytic judgement in EBM. A number of other analytic a priori tools follow
from this principle, including the judgements that: RCTs control extraneous or
confounding factors in an assessment of an intervention; confidence intervals
help distinguish between true effects and chance ones; and that summing re-
sults in meta-analyses produces a truer result than a single observation. The
hierarchy of evidence is not about the possibility of the elimination of bias, but
about the actual or real elimination of bias to reveal a pure relationship un-
cluttered by other things.
Internal validity is intrinsic to the hierarchy. The precept of internal validity
is that it is possible to be certain that the action of the independent variable is
the reaction in the dependent variable, that the measure of the reaction is true
and that if repeated under the same conditions it will produce the same degree
of change in the dependent variable. This is an a priori position because
empirically and after the fact, this can never be demonstrated; it is an ideal
position. And even empirically, it can only be demonstrated by controlling for
all possible confounders, something that is never attained in real life. More-
over, in medical practice, the way disease presents is not as a single entity but
frequently as multiple morbidities, that is, the patient has more than one thing
wrong with them. Therefore, the idea of simple causes and effects as implied
by the focus on internal validity in EBM is seldom the reality of medical pre-
sentations. Nevertheless, methods that are strong on control and on internal
validity sit at the top of the evidence hierarchy in EBM. The analytic a priori
judgement that follows from this is that it is possible to distinguish between
types of method on the basis of their ability to eliminate bias. This is an entirely
rationalist position that owes little to empirical science because the idea of
a real pure relationship between the independent and dependent variable is
only possible in the realm of pure reason and is about the relationship between
ideas. It is further based ontologically on the idea that single outcomes could
have single causes and that other things being equal these could be found and
measured precisely. All this reasoning operates in the world of ideas and pure
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reason, not empirical science. These principles are the basis for deductive
reasoning in EBM.
What the hierarchy of evidence attempts to do is describe a science in which
the elimination of bias is a real possibility and to privilege those methods that
control the extraneous factors out of the equation. They are givens; they are true
by reference to their meaning and to deny them would be self-contradictory.
None of this is to deny that bias introduced by the act of observation or fallible
human observers should not be minimised, or that science should not strive for
accuracy and objectivity. In this regard, the hierarchy serves well. However, its
fundamental principle is not about eliminating bias deriving from observa-
tion, but bias meaning eliminating distortions in the true relations between
phenomena.
Kant’s second set of judgements or rules are synthetic a posteriori judge-
ments. These are judgements that are made on the basis of observation,
can only be made after the fact and are in essence pure evidence, or more
precisely the representations of the reality that the evidence describes, or as
Kant would put it as they appear to be. Therefore, for example, the statement
that comparative effectiveness of compound x over compound y in cases of
disease z has n difference in effect size, is judged on the basis of its synthetic a
posteriori quality. It involves three after-the-fact observations, which are
brought together. The observation of what x does, the observation of what y
does and the difference between them. This is the core synthetic a posteriori
matter of fact at the heart of EBM, and indeed is often thought of as the very
quintessence of EBM and HTA. These matters of fact can then be the basis of
induction. The concept of effectiveness as against efficacy is synthetic and a
posteriori.
Kant’s third set of judgements are the synthetic a priori judgements. These
are required because, as both Hume and Kant noted, induction is a process
involving judgement and interpretation. Inductive reasoning needs more than
matters of fact. For Kant, it needs synthetic a priori judgements. These are
plentiful in EBM. Synthetic a priori judgements transcend the empiricist world
of synthetic a posteriori evidence of effectiveness and the rationalist analytic
a priori world of the hierarchy of evidence. The synthetic a priori judgements
bridge the two domains and without them EBM would be impossible.
The first example of synthetic a priori approach to illustrate the point is
medical diagnosis. Critical to the process are clinical judgement, disease labels
and observation. Diagnostic categories or disease labels are essential to
EBM and HTA, as a diagnostic category is normally the focus of the efforts to
determine clinical and cost effectiveness. Simplistically, it might be imagined
that diagnosis involves fitting the observed symptoms to the agreed disease
taxonomy. Taxonomies are familiar enough from any medical textbook, based
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on a variety of ways of arranging medical knowledge. Attached to disease
taxonomies are descriptions of the epidemiology, aetiology (if known), therape-
utics and prognostics. Taxonomies change as medical knowledge advances; they
are not fixed and immutable (Bell, 2010). The taxonomies are typifications that
can only exist in an ideal rationalist sense. This is because the way that
pathology manifests itself empirically in the human or in any animal or plant
does not follow the strict limits of the disease as described in the taxo-
nomy. The taxonomy is a social product that changes, not a fixed underlying
reality.
In any event, there is always variation. In part, this variation is associ-
ated with the individual biological and genetic difference referred to above. It
also arises because biological and genetic variations interact with different
aetiological agents. Empirically, disease is therefore a spectrum of pathology
and many patient presentations are a cluster of multiple pathologies and
morbidities. These will more or less approximate to the taxonomic ideal (Bell,
2010). Therefore, taxonomies not only change through time, they always have
to be used flexibly in diagnosis. Doctoring is not simply about fitting sets of
observed symptoms to taxonomies. Clinical judgement involves being flexi-
ble with the taxonomies. If all that medicine involved was applying the cate-
gories described in the textbook, then anyone who could read and understand
the textbook could be a doctor. Clinical training involves learning that the
categories are the necessary, but not sufficient condition for diagnosis – clinical
judgement is also involved. It is what is not in the textbook that is the basis
of the practice of clinical medicine. Therefore, the very concept of the identi-
fication via diagnosis of a particular disease is synthetic and a priori as it
rests, and is only possible, on the basis of empirical observation and clinical
judgement.
The synthetic a priori idea of diagnosis involving clinical judgement is a very
different type of judgement to applying the mechanics of the hierarchy of evi-
dence or a statistical test. The two ways of thinking sit decidedly uncomfortably
together in EBM. The certainties of the analytic a priori concepts of confidence
intervals, hierarchies of evidence and the elimination of bias are a long way
removed from the kinds of subjectivities involved in clinical judgement.
Therefore, many of the tensions associated with doing EBM can be seen to
revolve around the rationalist–empiricist divide and the contrast between the
processes of inductive reasoning associated with clinical activity and the deduc-
tive reasoning associated with the mechanics and techniques of EBM and
HTA (Barnett et al, 2009). Many of the critiques of EBM that arise precisely
because of these two ways of thinking – the synthetic a priori clinical judgement
versus the rule-driven certainties of EBM grounded in analytic a priori judge-
ments – are different (Egger et al, 2001). Both sides interestingly appeal to the
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evidence – the synthetic a posteriori concepts – as a rhetorical device to justify
their position (see Russell et al, 2008). Kant’s eighteenth-century epistemology
offers an explanation of this very modern problem.
The second key synthetic a priori idea is that of modelling, which is also at
the heart of the EBM/HTA enterprise and an area where the principles are hotly
contested. Economic modelling, which is such a central part of HTA, is founded
on the juxtaposition of different concepts; say the amount of health improve-
ment or quality of life gained as a consequence of the administration of such
and such a degree of medical intervention. This is the synthetic element. The
a priori element comes from the association that is known empirically to exist
in general terms between these two elements and the ability to predict a priori
that these elements will be conjoined in the future. Economic modelling is
classically synthetic and a priori.
The third example of the synthetic a priori group of concepts is external
validity (Campbell and Stanley, 1966). Unlike internal validity, which is an
a priori analytic concept, built entirely out of rationalist principles, external
validity is classically a priori and synthetic. External validity is conventionally
defined as dealing with the question of whether the results obtained in one
setting would apply in another (Campbell and Stanley, 1966). In EBM and HTA
classically, it is about determining whether the findings of one trial are trans-
ferable or generalisable more broadly. Statistical generalisability is usually
corralled in order to help reach the decision. Applied in EBM, it is about dealing
with the question of whether the results of study A will help patient B, and can
team C in hospital or primary care setting D implement it in such a way that it
will work as in study A. In areas where the judgements involve a long causal
chain from the intervention to the outcome as in public health or other social
care or educational interventions (Kelly et al, 2010; Kelly and Moore, 2010), the
problem of external validity is still more vexing (See also Pawson, 2002, 2006).
In these cases, we are trying to determine whether the results of study A, which
describes a rather loosely defined and often poorly specified intervention B,
applied in manner C, in context D, by team E, in organisation F, to sub popu-
lation G, will produce the same result as it did when it was originally done two
decades ago in study A (Moore and Rutherford, 2012). These judgements are
quintessentially and inevitably difficult. It is not going to be possible to derive
the judgements from better more highly powered studies, covering all sub
populations, nor to find all the details of the fidelity of the intervention or the
process of implementation (Davidson et al, 2003). Therefore, we have to use
synthetic a priori judgements if we are to work scientifically. In short, external
validity is empirical evidence conjoined with theory and is about probabilistic
statements in the face of real-world uncertainty; internal validity is about
rationalist certainty in the world of ideas.
The judgement process in evidence-based medicine and health technology assessment
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Conclusion
In some respects, the evidence-based approach may seem at first sight in the
critical sociological gaze to be little more than abstracted empiricism, and in
many ways it is its own worst enemy being locked into a particular view of itself
as the highest form of empirical medical science. Some proponents of EBM do
seem to have a very narrow conception of the enterprise in which evidence
based means empirically based, with theory and opinion being cast as the lower
orders of the hierarchy of evidence. However, thinking about EBM in a frame-
work of some of the ideas of Hume and Kant casts it into a different light.
Therefore, intriguingly, the evidence-based approach as applied in EBM and
HTA offers an illustration of Kant’s fundamental epistemological concepts in
action.
Arguably, this observation is of little interest to practitioners of the arts of
EBM and HTA, as it is perfectly possible to make an assessment of cost effec-
tiveness of a new pharmacological agent or to quality appraise a series of
systematic reviews without ever knowing anything of Kant or Hume. On the
other hand, articulating the judgement processes is interesting in itself. How-
ever, more importantly, the concepts outlined here can help illuminate some of
the real tensions that arise in trying to reach judgements in EBM and HTA,
where real uncertainty often surrounds the processes. The usual common sense
reaction to uncertainty by the practitioners of the arts of EBM and HTA is to try
to work harder and harder, like Boxer the horse in Orwell’s Animal Farm, to
perfect the methods that will eliminate the bias. They seldom recognise the fact
that they are straddling a very old intellectual divide, well known to Enlight-
enment philosophers.
Some agencies with HTA responsibilities have explicitly acknowledged
the tensions and sought to move beyond methodological to philosophical
solutions. NICE, for example, began quite early on to try to articulate ten-
sions and ways of resolving them in its Social Value Judgements Papers (NICE,
2008). The need for these arose amidst the realisation that evidence alone
did not speak for itself, that interpretative processes were involved in
making sense of the evidence and that the interpretive processes did not
themselves or could not themselves be derived from science per se. The cur-
rent article adds to that thinking by suggesting that certain philosophical
ideas can help to articulate or describe the judgemental and interpretive
processes involved. What this article has not considered, and which remain
important areas for consideration, are the discursive and rhetorical devices
used by the actors involved, the group dynamics and the way they overlay
the decision-making processes. However, those will be the subject of another
article.
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Notes
1 All references to Hume are taken from the 2007 Oxford University Press edition, Hume (1748/
2007) An Enquiry Concerning Human Understanding, Oxford: Oxford University Press. ed and
intro P. Millican. First published 1748.
2 All references to Kant are taken from the Kemp Smith translation in the Palgrave Macmillan
edition, Kant (1781, 1787/2007) The Critique of Pure Reason, trans Norman Kemp Smith,
introduction Howard Caygill, bibliography Gary Banham, Basingstoke: Palgrave/Macmillan.
3 The distinctions made by Kant were developed subsequently by John Stuart Mill (1843). Mill
distinguished between verbal and real propositions and between merely apparent and real
inferences. The distinction, Mill himself noted, corresponds to Kant’s analytic and synthetic
judgements. Mill differed from Kant by asserting that apparent inferences have no genuine
cognitive content. Pure mathematics and logic do, according to Mill, contain real positions and
have genuine cognitive content. In the final analysis, Mill held that all reasoning is empirical
through a process he called enumerative induction or simple generalisation from experience.
This he recognised was a fallible process (Skorupski, 2005). There are some striking similarities
between Kant and Mill, and it would be possible to use Mill as a basis to deconstruct EBM.
However, we propose that the original Kantian scheme of judgements offers the more helpful
way of describing the judgement process in EBM rather than subsequent empiricist or indeed
positivist arguments.
The judgement process in evidence-based medicine and health technology assessment
17r 2012 Macmillan Publishers Ltd. 1477-8211 Social Theory & Health Vol. 10, 1, 1–19
References
Barnett, D., Stevens, A., Boysen, M. and Longson, C. (2009) Developing evidence based guidance for
health technologies: The nice experience. In: A. Killoran and M.P. Kelly (eds.) Evidence Based
Public Health: Effectiveness and Efficiency. Oxford: Oxford University Press.
Bell, J. (2010) Redefining Disease. The Harveian Oration of 2010. London: Royal College of
Physicians.
Black, N. (1996) Why we need observational studies to evaluate the effectiveness of healthcare.
British Medical Journal 312(May): 1215–1218.
Blalock, H.M. (1970) An Introduction to Social Research. Engelwood Cliffs, NJ: Prentice Hall.
Campbell, D.T. and Stanley, J.C. (1966) Experimental and Quasi Experimental Designs for Research.
Chicago: Rand McNally.
Centre for Reviews and Dissemination. (2008) Systematic Reviews: CRD’s Guidance for Undertaking
Reviews in Healthcare. York: Centre for Reviews and Dissemination, University of York.
Cochrane, A.L. (1972) Effectiveness and Efficiency: Random Reflections on Health Services. London:
British Medical Journal/Nuffield Provincial Hospitals Trust.
Culyer, A.J. (2006) The bogus conflict between efficiency and equity. Health Economics 15(11):
1155–1158.
Culyer, A.J., Lavers, R.J. and Williams, A. (1972) Health indicators. In: A. Shonfield and S. Shaw
(eds.) Social Indicators and Social Policy. London: Heinemann.
Davidson, K. et al (2003) Evidence – based behavioral medicine: What it is and how do we achieve
it? Annals of Behavioral Medicine 26(3): 161–171.
Drummond, M.F., Sculpher, M.J., Torrance, G.W., O’Brien, B.J. and Stoddart, G.L. (2005)
Methods for the Evaluation of Healthcare Programmes, 3rd edn. Oxford: Oxford University Press.
Drummond, M. et al (2007) Assessing the Challenges of Applying Standard Methods of Economic
Evaluation to Public Health Interventions, Public Health Research Consortium, Final Report York:
University of York.
Egger, M., Davey Smith, G. and Altman, B.G. (2001) Systematic Reviews in Health Care:
Meta-Analysis in Context. London: BMJ Books.
Glasziou, P., Chalmers, I., Rawlins, M. and McCulloch, P. (2007) When are randomised trials
unnecessary? Picking signal from noise. British Medical Journal 334(February): 349–351.
Greenhalgh, T. (2001) How to Read a Paper: The Basics of Evidence Based Medicine. London: BMJ
Books.
Guyer, P. (2006) Kant. London: Routledge.
Hume, D. (1748/2007) An Enquiry Concerning Human Understanding. Oxford: Oxford University
Press, P. Millican (ed. and intro.). First published 1748.
Kant, I. (1781, 1787/2007) The Critique of Pure Reason, Translated by Norman Kemp
Smith, Introduction Howard Caygill, bibliography Gary Banham. Basingstoke, UK: Palgrave/
Macmillan.
Kelly, M.P. and Moore, T.A. (2010) Making a Difference: Using the NICE Public Health Guidance
and Embedding Evaluation. London: IDEA.
Kelly, M.P., Morgan, A., Ellis, S., Younger, T., Huntley, J. and Swann, C. (2010) Evidence based
public health: A review of the experience of the national institute of health and clinical excellence
(NICE) of developing public health guidance in England. Social Science and Medicine 71:
1056–1062.
Korner, S. (1955) Kant. Harmondsworth, UK: Penguin.
Lomas, J., Culyer, T., McCutcheon, C., McCAuley, L. and Law, S. (2005) Conceptualizing and
Combining Evidence for Health System Guidance. Ottawa, Canada: Canadian Health Services
Research Foundation.
Mill, J.S. (1843/1947) A System of Logic. London: New impression, Longmans, Green, 1947.
Kelly and Moore
18 r 2012 Macmillan Publishers Ltd. 1477-8211 Social Theory & Health Vol. 10, 1, 1–19
Millican, P. (2007) Introduction Hume’s Enquiry Concerning Human Understanding. Oxford: Oxford
University Press.
Moore, T.A and Rutherford, D. (2012) Primary strategy learning networks: A local study of a national
initiative. Educational Management Administration and Leadership, published online before
print, 15 November 2011, doi: 10.1177/1741143211420612.
NICE. (2008) Social Value Judgements: Principles for the Development of NICE Guidance, 2nd edn.
London: NICE, http://www.nice.org.uk/media/C18/30/SVJ2PUBLICATION2008.pdf, accessed 17
November 2011.
NICE. (2009) Methods for the Development of NICE Public Health Guidance, 2nd edn. London:
NICE, http://www.nice.org.uk/aboutnice/howwework/developingnicepublichealthguidance/public
healthguidanceprocessandmethodguides/public_health_guidance_process_and_method_guides
.jsp?domedia=1&mid=F6A97CF4-19B9-E0B5-D42B4018AE84DD51, accessed 17 November 2011.
Orne, M.T. (1970) On the social psychology of the psychological experiment: with particular
reference to the demand characteristics and their implications. In: Denzin, N.K. (ed.) Sociological
Methods: A Sourcebook. Chicago: Aldine.
Pawson, R. (2002) Evidence based policy: In search of a method. Evaluation 8(2): 157–181.
Pawson, R. (2006) Evidence Based Policy: A Realist Perspective. London: Sage.
Pickstone, J.V. (2007) Working knowledges before and after circa 1800: Practices and disciplines in
the history of science, technology and medicine. Isis 98(3): 489–516.
Rawlins, M. (2008) De Testimonio: On the Evidence for Decisions About the Use of Therapeutic
Interventions, The Harveian Oration of 2008. London: Royal College of Physicians.
Russell, J., Greenhalgh, T., Byrne, E. and McDonnell, J. (2008) Recognizing rhetoric in health care
policy analysis. Journal of Health Services Research and Policy 13(1): 40–46.
Sackett, D.L., Rosenberg, W.M.C., Gray, J.A.M., Haynes, R.B and Richardson, W.S. (1996) Evidence
based medicine: What it is and what it isn’t. British Medical Journal 312: 71–72.
Sorensen, C., Drummond, M., Børlum Kristensen, F. and Busse, R. (2010) How can the impact
of health technology assessments be enhanced? Policy brief, World Health Organization on behalf
of the European Observatory on Health Systems and Policies, http://bit.ly/a1NxTR, accessed 17
November 2011.
Skorupski, J. (2005) The Oxford Companion to Philosophy, In: J.S. Mill and T. Honderich (eds.)
2nd edn. Oxford: Oxford University Press, pp. 599–602.
Vandenbroucke, J.P. (2008) Observational research, randomised trials, and two views of medical
science. PLoS Med 5(3): e67.
Ward, A. (2006) Kant: The Three Critiques. Cambridge: Polity.
Weldon, T.D. (1958) Kant’s Critique of Pure Reason, 2nd edn. Oxford: Clarendon.
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivative Works 3.0 Unported License. To
view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
The judgement process in evidence-based medicine and health technology assessment
19r 2012 Macmillan Publishers Ltd. 1477-8211 Social Theory & Health Vol. 10, 1, 1–19
